Currently, research is primarily focusing on the role of PDHB in cancer, particularly in the cuproptosis pathway associated with non-alcoholic fatty liver disease (NAFLD), where both DLD and PDHB are potential candidate genes for NAFLD diagnosis and treatment options (49). Here, PDHB is linked to metabolic dysfunction-associated steatotic liver disease.